Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.78 |
| ▸ | NAAA | Q02083 | 1/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.61 |
| ▸ | POLB | P06746 | 2/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.61 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.59 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.56 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.55 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.55 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.55 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.55 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.55 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.55 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7825903 | 0.93 | CYP1A2 (0.88) | CYP1A2CYP2C9CYP2C19MAPK1NAAA | |
| SCHEMBL16469025 | 0.90 | NAAA (0.83) | CYP1A2CYP2C9CYP2C19MAPK1NAAA | |
| SCHEMBL428355 | 0.88 | MAPK1 (1.00) | CYP1A2CYP2C9CYP2C19MAPK1NAAA | |
| SCHEMBL3203823 | 0.86 | CYP1A2 (0.76) | CYP1A2CYP2C9CYP2C19MAPK1NAAA | |
| SCHEMBL5655215 | 0.85 | MAPK1 (0.86) | CYP1A2CYP2C9CYP2C19MAPK1NAAA | |
| SCHEMBL1231651 | 0.85 | MAPK1 (0.86) | CYP1A2CYP2C9CYP2C19MAPK1NAAA | |
| SCHEMBL10659200 | 0.85 | MAPK1 (0.86) | CYP1A2CYP2C9CYP2C19MAPK1NAAA | |
| SCHEMBL10865398 | 0.85 | MAPK1 (0.86) | CYP1A2CYP2C9CYP2C19MAPK1NAAA | |
| SCHEMBL9183154 | 0.83 | MAPK1 (0.90) | CYP1A2CYP2C9CYP2C19MAPK1NAAA | |
| SCHEMBL26661152 | 0.83 | CYP1A2 (0.71) | CYP1A2CYP2C9CYP2C19MAPK1NAAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2409569-B1 | Method for administering GLP-1 molecules | EMISPHERE TECH INC (US) | 2017-08-16 | — | — | EP | disclosed |
| EP-1478233-B1 | METHOD FOR ADMINISTERING GLP-1 MOLECULES | EMISPHERE TECH INC (US) | 2016-11-09 | — | — | EP | disclosed |
| US-20150202296-A1 | METHOD FOR ADMINISTERING GLP-1 MOLECULES | NOVO NORDISK NORTH AMERICA OPERATIONS A/S (DK) | 2015-07-23 | — | — | US | disclosed |
| US-20150202296-A1 | METHOD FOR ADMINISTERING GLP-1 MOLECULES | NOVO NORDISK NORTH AMERICA OPERATIONS A/S (DK) | 2015-07-23 | — | — | US | disclosed |
| US-8492330-B2 | Formulation comprising GLP-1 | EMISPHERE TECHNOLOGIES, INC. (US) | 2013-07-23 | — | — | US | disclosed |
| US-8492330-B2 | Formulation comprising GLP-1 | EMISPHERE TECHNOLOGIES, INC. (US) | 2013-07-23 | — | — | US | disclosed |
| EP-2409569-A2 | Method for administering GLP-1 molecules | Emisphere Technologies, Inc. (US) | 2012-01-25 | — | — | EP | disclosed |
| US-20110178006-A1 | METHOD FOR ADMINISTERING GLP-1 MOLECULES | EMISPHERE TECHNOLOGIES, INC. (US) | 2011-07-21 | — | — | US | disclosed |
| US-20110178006-A1 | METHOD FOR ADMINISTERING GLP-1 MOLECULES | EMISPHERE TECHNOLOGIES, INC. (US) | 2011-07-21 | — | — | US | disclosed |
| US-7939494-B2 | Method for administering GLP-1 molecules | EMISPHERE TECHNOLOGIES, INC. (US) | 2011-05-10 | — | — | US | disclosed |
| US-7939494-B2 | Method for administering GLP-1 molecules | EMISPHERE TECHNOLOGIES, INC. (US) | 2011-05-10 | — | — | US | disclosed |
| US-20090286735-A1 | METHOD FOR ADMINISTERING GLP-1 MOLECULES | NOVO NORDISK NORTH AMERICA OPERATIONS A/S (DK) | 2009-11-19 | — | — | US | disclosed |
| US-20090286735-A1 | METHOD FOR ADMINISTERING GLP-1 MOLECULES | NOVO NORDISK NORTH AMERICA OPERATIONS A/S (DK) | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150202296-A1 | METHOD FOR ADMINISTERING GLP-1 MOLECULES | GLP1R, GIPR, GPR119 | CYP1A2 2415/4885CYP2C9 1591/4885CYP2C19 1075/4885 |
| US-20110178006-A1 | METHOD FOR ADMINISTERING GLP-1 MOLECULES | GLP1R, GIPR, GPR119 | CYP1A2 2415/4885CYP2C9 1591/4885CYP2C19 1075/4885 |
| US-20090286735-A1 | METHOD FOR ADMINISTERING GLP-1 MOLECULES | GLP1R, GIPR, GPR119 | CYP1A2 2415/4885CYP2C9 1591/4885CYP2C19 1075/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.